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Dappears limited in its predictive capacity for very–high-risk
patients with estimated risk>25.0%. These data provide a
strong foundation for further study to determine if 1%
mortality for CABG is achievable nationwide.
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Dr Todd Rosengart (Houston, Tex). Congratulations on an
excellent study and thank you for allowing me to see your manu-
script in advance. This is important work and you present very
interesting results.2696 The Journal of Thoracic and Cardiovascular SurOne of the most striking findings of your study is the apparent
implication of the failure to prescribe statins, beta-blockers, and
aspirin before discharge. Dr Ralph Damiano was perhaps the first
to suggest that maybe the greatest priority of an organization such
as American Association of Thoracic Surgery and Society of
Thoracic Surgeons should be to focus on a ‘‘get with the guide-
lines’’ campaign to improve outcomes, similar to the American
Hospital Association program. Based on your analysis, do you
think improvements in the rates of drug administrations would
have affected outcomes?
Dr LaPar.When we modeled out all 30 different variables that
go into calculating the Society of Thoracic Surgeons predicted risk
of mortality score, took into account individual surgeon volume,
and the accepted process of care measures for coronary artery
bypass grafting, we found that beta-blockers, statins, and aspirin
actually had the highest strength of association with predicted
mortality rate in both of our cohorts and, in fact, that strength of
association was significantly stronger in the cohort of patients
with higher risk. So absolutely process of care measures are some-
thing we need to focus on if we are going to attempt achieving the
<1% mortality goal in all of our efforts to reduce mortality related
to coronary artery bypass grafting.
Dr Rosengart. Although the ambitious goal of<1% mortality
across the board is certainly admirable, it would be difficult to
expect that patients with predicted mortality of 25% or higher
where even the predicted risk of mortality analysis becomes unpre-
dictive of outcome could be taken care of with<1%mortality. You
mentioned that 60% of a target population might be appropriate for
a targeted 1% mortality outcome, but will you comment further on
those highest-risk patients? What percentage of the population
were they and what were the implications of accepting the fact
that these clearly are not patients who can undergo surgery due
to their low expected mortality rates?
Dr LaPar. I think that is an essential point. One of the things
we were concerned about initially was exactly how many patients
were actually going to be able to achieve this end point, because a
number of institutions within our quality initiative (as well as many
represented here) do in fact operate on patients who are at signif-
icantly higher risk. That has notable policy implications. We need
to be very careful that we do not set ourselves up to have hospitals
referring more and more patients with higher risk to some of the
institutions represented in our analysis while we are charged
with trying to achieve a very low mortality rate. It may not be
achievable in those patients.
Dr Rosengart. I was hoping you could comment further
on the implications of surgeon and institution case volume.
It clearly was not as significant a factor as drug administration,
but did you do any further subanalyses to look at the im-
plication?
Dr LaPar. We did not do any specific subgroup analyses
looking at surgeon volume. We did demonstrate a significant rela-
tionship between surgeon and institution volume. We included a
smoothing function and we believe that surgeon experience and
surgeon volume clearly are important.
It would be interesting to look at surgeon experience over
time—because surgeons get better as they advance through their
careers—to see where that correlates with predicted risk and these
goals. We plan to look at that in the future.gery c December 2014
